Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA): Price and Financial Metrics
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
Today's Latest Price: $8.80 USD
Updated Sep 28 4:10pm
Add TEVA to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
TEVA Stock Summary
- Teva Pharmaceutical Industries Ltd's stock had its IPO on March 26, 1990, making it an older stock than 84.63% of US equities in our set.
- With a price/earnings ratio of 2,388.79, Teva Pharmaceutical Industries Ltd P/E ratio is greater than that of about 99.63% of stocks in our set with positive earnings.
- Teva Pharmaceutical Industries Ltd's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 25.16%, greater than the shareholder yield of 89.23% of stocks in our set.
- Stocks that are quantitatively similar to TEVA, based on their financial statements, market capitalization, and price volatility, are HAS, JHX, OTEX, WAB, and AIMC.
- TEVA's SEC filings can be seen here. And to visit Teva Pharmaceutical Industries Ltd's official web site, go to www.tevapharm.com.
TEVA Stock Price Chart Technical Analysis Charts
TEVA Price/Volume Stats
| Current price | $8.80 | 52-week high | $13.76 |
| Prev. close | $8.72 | 52-week low | $6.25 |
| Day low | $8.70 | Volume | 4,402,971 |
| Day high | $8.88 | Avg. volume | 14,511,451 |
| 50-day MA | $10.36 | Dividend yield | N/A |
| 200-day MA | $10.68 | Market Cap | 9.61B |
Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) Company Bio
Teva Pharmaceuticals manufactures, markets, and distributes generic, specialty, and other pharmaceutical products worldwide. The company operates in two segments, Generic Medicines and Specialty Medicines. The company was founded in 1901 and is based in Petach Tikva, Israel.
TEVA Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $8.80 | $1.15 | -87% |
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Teva Pharmaceutical Industries Ltd. To summarize, we found that Teva Pharmaceutical Industries Ltd ranked in the 12th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 86.83%. As for the metrics that stood out in our discounted cash flow analysis of Teva Pharmaceutical Industries Ltd, consider:
- Its compound free cash flow growth rate, as measured over the past 5.49 years, is -0.24% -- higher than only 6% of stocks in our DCF forecasting set.
- 26% of the company's capital comes from equity, which is greater than merely 11.62% of stocks in our cash flow based forecasting set.
- As a business, Teva Pharmaceutical Industries Ltd experienced a tax rate of about 0% over the past twelve months; relative to its sector (Healthcare), this tax rate is higher than just 0% of stocks generating free cash flow.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -87% |
| 1% | -87% |
| 2% | -87% |
| 3% | -87% |
| 4% | -87% |
| 5% | -86% |
Want more companies with a valuation profile/forecast similar to that of Teva Pharmaceutical Industries Ltd? See BLFS, IDXX, PCRX, ELAN, and EW.
Loading social stream, please wait...